Inventor

STEVANOVIC STEFAN

DE52 patents

⚠️ This page may combine multiple inventors who share the name “STEVANOVIC STEFAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

STEVANOVIC STEFAN

IMMATICS BIOTECHNOLOGIES GMBH

Powerful MHC-class II peptides derived from survivin

Tumor-associated peptides that bind to MHC-molecules

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

Tumour-associated peptides binding to MHC-molecules

Tumour-associated peptides binding to MHC-molecules

Tumor-associated peptides binding to MHC-molecules

Powerful MHC-class II peptides derived from survivin

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Peptide for triggering an immune reaction against tumor cells

Peptide for triggering an immune reaction against tumor cells

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Peptides and combination thereof for use in the immunotherapy against cancers

Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers

Peptides and combination thereof for use in the immunotherapy against cancers

Peptides and combination thereof for use in the immunotherapy against cancers

Peptides and combination thereof for use in the immunotherapy against cancers

Peptides and combination thereof for use in the immunotherapy against cancers

Peptides and combination thereof for use in the immunotherapy against cancers

Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers

Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

WEINSCHENK TONI

Tumour-associated peptides that bind to MHC molecules

Tumour-associated peptides that bind to MHC molecules

HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

MHC molecule-binding tumor-associated peptides

RAMMENSEE HANS-GEORG

Powerful MHC-class II peptides derived from survivin

Powerful MHC-class II peptides derived from survivin

LUDWIG INST CANCER RES

Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules

Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof

MAX PLANCK GESELLSCHAFT

Determination of peptide motifs on MHC molecules

RAMMENSEE HANS GEORG

HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof